Frontiers reaches 6.4 on Journal Impact Factors

This article is part of the Research Topic

Transfusion Medicine and Blood

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Med. | doi: 10.3389/fmed.2018.00033

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

 Victor Drew1,  Ching-Li Tseng1, Jerard Seghatchian2 and  Thierry Burnouf1*
  • 1Taipei Medical University, Taiwan
  • 2International Consultancy in Blood Components Quality/Safety Improvement, Audit/Inspection and DDR Strategies, United Kingdom

Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears, and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. While the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctual occlusion, recently, standardized non components blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

Keywords: Dry eye syndrome, serum eye drop, Platelet lysate, Blood, Treatment

Received: 02 Nov 2017; Accepted: 30 Jan 2018.

Edited by:

Michel Prudent, Transfusion Interrégionale CRS SA, Switzerland

Reviewed by:

Coen Maas, University Medical Center Utrecht, Netherlands
Dirk D. Korte, Sanquin, Netherlands  

Copyright: © 2018 Drew, Tseng, Seghatchian and Burnouf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Thierry Burnouf, Taipei Medical University, Taipei, Taiwan,